Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Small Cell Lung Carcinoma 2Neoplasm Metastasis 2Sezary Syndrome 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1

Interventions

Rituximab 48Cyclophosphamide 27Lenalidomide 23Peripheral Blood Stem Cell Transplantation 16obinutuzumab 10fludarabine phosphate 10Filgrastim 10Etoposide 10Bendamustine Hydrochloride 10Vincristine 8Prednisone 8Doxorubicin 8fludarabine 7Radiotherapy 7Mycophenolic Acid 7Melphalan 7Cyclosporine 7Bortezomib 7venetoclax 6tazemetostat 6ibritumomab tiuxetan 6Whole-Body Irradiation 6Gemcitabine 6pembrolizumab 5ibrutinib 5Ifosfamide 5Granulocyte Colony-Stimulating Factor 5CT-P10 5veltuzumab 4Methotrexate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Follicular × navitoclax × Clear all
NCT00406809 2021-08-02

A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

AbbVie

Phase 1/2 Completed
81 enrolled
DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Sezary Syndrome, Leukemia, B-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡